Make earnings with no risk
Automated AI-driven system makes the trades, you earn the money
Join now

Positive Results in Phase 3 Study of Pyrukynd for Thalassemia Patients


By Colin Kellaher

Shares of Agios Pharmaceuticals saw a significant rise in premarket trading on Wednesday following the announcement of positive outcomes from a late-stage study of its Pyrukynd anemia drug. The study demonstrated successful achievement of its goals in certain patients with thalassemia, an inherited blood disorder.

Phase 3 Study Highlights

Agios reported that the Phase 3 study of Pyrukynd in adults with non-transfusion-dependent alpha- or beta-thalassemia reached its primary endpoint of hemoglobin response. Additionally, the study also showed statistical significance for a pair of key secondary endpoints.

These study results suggest that Pyrukynd may hold potential as the first oral therapy for all non-transfusion-dependent thalassemia patients, including those with alpha- or beta-thalassemia.

Future Plans and Regulatory Approval

Agios stated that it anticipates announcing topline data from a separate Phase 3 study of Pyrukynd in adults with transfusion-dependent alpha- or beta-thalassemia by mid-2024. Furthermore, the company plans to submit the drug for regulatory approval as a thalassemia treatment by the end of this year.

Pyrukynd’s Current Approvals

Currently, Pyrukynd is approved in the U.S. for treating hemolytic anemia in adults with pyruvate-kinase deficiency. It is also approved in the European Union for the treatment of pyruvate-kinase deficiency in adults.

Stock Performance

Agios shares closed at $22.83 on Tuesday and experienced a 14% surge to $26 during premarket trading.

Federal Reserve Signals Three Rate Cuts in 2022

Previous article

VinFast Auto: A Bright Future Ahead

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News